Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial

Critical Care Medicine

Volumn 31, Issue 3, 2003, Pages 834-840

  Vincent, Jean Louis ^a   Angus, Derek C ^b   Artigas, Antonio ^c,d   Kalil, Andre ^e   Basson, Bruce R ^e   Jamal, Hassan H ^e   Johnson III, Gerald ^e   Bernard, Gordon R ^f  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Critical Care Center   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e ELI LILLY AND COMPANY   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activated protein C; Drotrecogin alfa (activated); Morbidity; Organ dysfunction; Sepsis; Sequential Organ Failure Assessment

Indexed keywords

DROTRECOGIN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SEPSIS;

AGED; ANTI-INFECTIVE AGENTS; APACHE; CAUSE OF DEATH; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORBIDITY; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDIES; PROTEIN C; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037352375     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000051515.56179.E1     Document Type: Article

References (24)

1. Esmon CT, Taylor FB Jr, Snow TR: Inflammation and coagulation: Linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991; 66:160-165
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
3. Zimmerman JE, Knaus WA, Wagner DP, et al: A Comparison of risks and outcomes for patients with organ system failure: 1982-1990. Crit Care Med 1996; 24:1633-1641
4. Marietta JO, Bertleff E, Bruining HA: How should multiple organ dysfunction syndrome be assessed? A review of the variations in current scoring systems. Eur J Surg 1997; 163:405-409
5. Warren BL, Eid A, Singer P, et al: High-dose antithrombin III in severe sepsis: A randomized controlled trial. Kypercept Trial Study Group. JAMA 2001; 286:1869-1878
6. Abraham E, Laterre PF, Garbino J, et al: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Lenercept Study Group. Crit Care Med 2001; 29:503-510
7. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock: NORACEPT II Study Group. Lancet 1998; 351:929-933
8. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
9. Esmon CT: The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12:135-145
10. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-710
11. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
12. Vincent JL, de Mendonca A, Cantraine F, et al: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Crit Care Med 1998; 26:1793-1800
13. Ferriera FL, Bota DP, Bross A, et al: Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001; 286:1754-1758
14. Marubini E, Valsecchi MG: Analysing Survival Data from Clinical Trials and Observational Studies. New York, John Wiley and Sons, 1995, pp 113-117
15. Walker FJ, Sexton PW, Esmon CT: The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochim Biophys Acta 1979; 571:333-342
16. Fulcher CA, Gardiner JE, Griffin JH, et al: Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984; 63:486-489
17. Sakata Y, Loskutoff DJ, Gladson CL, et al: Mechanism of protein C-dependent clot lysis: Role of plasminogen activator inhibitor. Blood 1986; 68:1218-1223
18. Vervloet MG, Thijs LG, Hack CE: Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998; 24:33-44
19. Levi M, de Jonge E, van der Poll T, et al: Novel approaches to the management of disseminated intravascular coagulation. Crit Care Med 2000; 28:S20-S24
20. Levi M, ten Cate H, van der Poll T, et al: Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270:975-979
21. Coalson JJ: Pathology of Sepsis, Septic Shock, and Multiple Organ Failure: Perspective on sepsis and septic shock. Fullerton, CA, Society of Critical Care Medicine, 1986, pp 27-59
22. Grinnell BW, Hermann RB, Yan SB: Human protein C inhibits selectin-mediated cell adhesion: Role of unique fucosylated oligosaccharide. Glycobiology 1994; 4:221-225
23. Joyce DE, Gelbert L, Ciaccia A, et al: Gene expression profile of antithrombotic protein C defines new mechanism modulating inflammation and apoptosis. J Biol Chem 2001; 276:11199-11203
24. Knaus WA, Draper EA, Wagner DP, et al: Prognosis in acute organ-system failure. Ann Surg 1985; 202:685-693